


FAST RELIEF¹
of neuropathic
pain symptoms



Significantly reduced
SLEEP DISTURBANCE²



Low potential for pharmacokinetic
DRUG INTERACTIONS^{3,4}



WELL TOLERATED
with long term **SAFETY PROFILE⁵**

Recommended



**ST
LINE**
treatment for
Neuropathic Pain*

*Attal N, et al. 2010



LYRICA®: Simple Dosing Regimen with Wide Indication⁴



The dose range is 150–600 mg/day given in either two or three divided doses. LYRICA® may be taken with or without food. If LYRICA® has to be discontinued, it is recommended this should be done gradually over a minimum of 1 week.

Neuropathic Pain		Fibromyalgia		Generalized Anxiety Disorder		Epilepsy	
Recommended starting dose	150 mg/day	Recommended starting dose	150 mg/day	Recommended starting dose	150 mg/day	Recommended starting dose	150 mg/day
*Titrate interval of 3–7 days	300 mg/day	*Titrate within 1 week	300 mg/day	*Titrate after 1 week	300 mg/day	*Titrate after 1 week	300 mg/day
Maximum dose after an additional 7-day interval	600 mg/day	**Titrate	450 mg/day	***Titrate	450 mg/day	Maximum dose after an additional week	600 mg/day
		Maximum dose after an additional week	600 mg/day	Maximum dose after an additional week	650 mg/day		

*Dosage may be increased to 300 mg/day based on individual patient response and tolerability.

**Patients who do not experience sufficient benefit with 300 mg/day may be further increased to 450 mg/day (225 mg BID).

***Following an additional week the dosage may be increased to 450 mg/day. The need for treatment should be reassessed regularly.

References:

1. Freeman R, et al. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy. *Diabetes Care*. 2008;31(7):1448–54. 2. Taguchi T, et al. Effectiveness of pregabalin for the treatment of chronic low back pain with accompanying lower limb pain (neuropathic component): A non-interventional study in Japan. *J Pain Res*. 2015;8:487–97. 3. Johnston SS, et al. Cost comparison of drug–drug and drug–condition interactions in patients with painful diabetic peripheral neuropathy treated with pregabalin versus duloxetine. *Am J Health-Syst Pharm*. 2013;70:2207–17. 4. Malaysia Lyrica Prescribing Information. October 2021 5. Satoh J, et al. Efficacy and safety evaluation of pregabalin treatment over 52 weeks in patients with diabetic neuropathic pain extended after a double-blind placebo-controlled trial. *J Diabetes Invest*. 2011;2(6):457–63.

*Attal N, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. *Eur J Neurol*. 2010;17:1113–23.

BID: Twice Daily

Scan QR Code
for LYRICA® Abbreviated
Prescribing Information



<http://viatrismyapi-lyrica.com>

Scan QR Code
for Neuropathic Pain
Assessment Tool



<http://www.painscreeningtool.com>

© 2022 Viatris Inc. All Rights Reserved

For Healthcare Professionals Only

LYR-2022-1019-MY-20APRIL2022



Full prescribing information is available on request
Market Authorisation Holder
Viatris Sdn. Bhd.

Reg. No: 201801018158 (1280174-H), (formerly known as Upjohn (Malaysia) Sdn. Bhd.)
15-03 & 15-04, Level 15, Imazium, No. 8, Jalan SS 21/37, Damansara Uptown, 47400, Petaling Jaya,
Selangor, Malaysia. Tel: 603-7733 8005